Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and in

Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth an

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 27.34% on an annu

Royalty Pharma (NASDAQ:RPRX) has outperformed the market over the past 10 years by 26.07% on an annu

Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the compa

NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agr

Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase a

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporti

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in

Royalty Pharma (RPRX) came out with quarterly earnings of $1.32 per share, beating the Zacks Consens

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst c

Portfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14% Net cash provided by

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for s

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks E

NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the ap

U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lo

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnin

Bank of New York Mellon Corp decreased its position in Royalty Pharma PLC (NASDAQ: RPRX) by 2.8% dur

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that i

Neurimmune announced today that it has sold a portion of its royalty interest in cliramitug to Royal

AlTi Global Inc. trimmed its position in Royalty Pharma PLC (NASDAQ: RPRX) by 50.5% in the first qua

Chicago Partners Investment Group LLC purchased a new stake in Royalty Pharma PLC (NASDAQ: RPRX) in

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RP

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should c

TD Cowen analyst Steve Scala maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the pri

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmen

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

JP Morgan analyst Chris Schott maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and raise

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst c

Morgan Stanley analyst Terence Flynn maintains Royalty Pharma (NASDAQ:RPRX) with a Overweight and

Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agr

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with rep

Zymeworks Inc. (NASDAQ:ZYME) and Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst c

Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being

Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including re

Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer dr

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr

Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Thera